A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients With Advanced or Metastatic Solid Tumors
This study is testing a new experimental drug called CPO301 to see how it works against advanced solid tumors, including lung cancer. Researchers want to learn if this drug is safe, what the best dose is, and if it can help shrink or control tumors.
This study is for adults aged 18 and older who have a solid tumor that has spread or returned after previous treatments. You must be able to perform your daily activities and have a tumor that can be clearly tracked by medical imaging.
Participants will receive the study drug through an IV injection every three weeks. You will need to visit the clinic regularly for check-ups and monitoring to see how your body reacts to the treatment and whether the cancer is responding.
The study is currently recruiting patients at medical centers in Los Angeles, Newport Beach, and Santa Monica, California. You will be followed by your medical team for up to two years.
- 1The drug being tested (CPO301) is an antibody-drug conjugate, which is designed to target cancer cells directly.
- 2This is a Phase 1 study, which primarily focuses on finding the safest and most effective dose for patients.
- 3Participation requires being able to attend regular clinic visits for monitoring and scans.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.